Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
During the past 12 months, Mettler-Toledo International's average EBITDA Per Share Growth Rate was 10.00% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 3.30% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 9.20% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 12.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Mettler-Toledo International was 20.70% per year. The lowest was 2.70% per year. And the median was 12.00% per year.
Mettler-Toledo International (FRA:MTO) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Mettler-Toledo International 3-Year EBITDA Growth Rate Related Terms
FRA:MTO vs DGX, LH, ILMN: 3-Year EBITDA Growth Rate Comparison
For the Diagnostics & Research subindustry, Mettler-Toledo International's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mettler-Toledo International 3-Year EBITDA Growth Rate vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Mettler-Toledo International's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Mettler-Toledo International's 3-Year EBITDA Growth Rate falls into.
Mettler-Toledo International 3-Year EBITDA Growth Rate Calculation
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 3.30% mean?
Mettler-Toledo International (FRA:MTO) has a 3-Year EBITDA Growth Rate of 3.30% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Mettler-Toledo International and its competitors. This is 73% below median its historical median of 12.00. Over the past decade, Mettler-Toledo International's 3-Year EBITDA Growth Rate has ranged from 2.70 to 20.70. According to the industry distribution chart, Mettler-Toledo International ranks #99 out of 165 companies in the Medical Diagnostics & Research industry, placing it in the top 60%.
Is Mettler-Toledo International's 3-Year EBITDA Growth Rate too high?
Mettler-Toledo International's current 3-Year EBITDA Growth Rate of 3.30% is 73% below median its 10-year median of 12.00. Over the past 10 years, this metric has ranged from a low of 2.70 to a high of 20.70. The Medical Diagnostics & Research industry median 3-Year EBITDA Growth Rate is 11.50. Mettler-Toledo International's value of 3.30% is 71.3% below this industry median. Based on the distribution chart, Mettler-Toledo International ranks #99 out of 165 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Mettler-Toledo International has a GF Score™ of 96/100, reflecting its overall financial health beyond just this single metric.
How does Mettler-Toledo International's 3-Year EBITDA Growth Rate compare to DGX and LH?
According to the Medical Diagnostics & Research industry distribution chart, Mettler-Toledo International ranks #99 out of 165 companies for 3-Year EBITDA Growth Rate. This places Mettler-Toledo International in the lower half of its industry. The industry median 3-Year EBITDA Growth Rate is 11.50. Mettler-Toledo International's value of 3.30% is 71.3% below this benchmark. Historically, Mettler-Toledo International's own 3-Year EBITDA Growth Rate has ranged from 2.70 to 20.70 over the past decade. While the company's 10-year median is 12.00 vs. the industry median of 11.50, Mettler-Toledo International has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Medical Diagnostics & Research company?
The median 3-Year EBITDA Growth Rate among Medical Diagnostics & Research companies is 11.50, based on 165 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Mettler-Toledo International's current 3-Year EBITDA Growth Rate of 3.30% is 71.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Mettler-Toledo International and its competitors. For the Medical Diagnostics & Research industry, the median 3-Year EBITDA Growth Rate is 11.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Mettler-Toledo International's current 3-Year EBITDA Growth Rate is 3.30%, which is 73% below median its own 10-year median of 12.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mettler-Toledo International stock overvalued right now?
Mettler-Toledo International (FRA:MTO) has a current 3-Year EBITDA Growth Rate of 3.30%. The stock's GF Value™ is €1,229.32, compared to a current price of €1,228.00 — trading 0.1% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 3.30%, which is 73% below median its 10-year median of 12.00 and 71.3% below the Medical Diagnostics & Research industry median of 11.50. Mettler-Toledo International's overall GF Score™ is 96/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Mettler-Toledo International (FRA:MTO), the current 3-Year EBITDA Growth Rate is 3.30% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Mettler-Toledo International (FRA:MTO) Overvalued in 2026?
Based on GuruFocus' analysis, Mettler-Toledo International stock appears to be undervalued.
The current stock price of €1,228.00 is trading 0.1% below its estimated GF Value™ of €1,229.32.
Key valuation signals for FRA:MTO:
3-Year EBITDA Growth Rate: 3.30% (73% below median its 10-year median of 12.00)
GF Value™: €1,229.32 vs. price of €1,228.00 (0.1% below fair value)
Industry Position: 71.3% below the Medical Diagnostics & Research median (#99 of 165)
No single metric tells the full story. See the FRA:MTO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Mettler-Toledo supplies weighing and precision instruments to customers in the life sciences (around 55% of sales), industrial (around 40%), and food retail (around 5%) industries. Its products include laboratory and retail scales, pipettes, pH meters, thermal analysis equipment, titrators, metal detectors, and X-ray analyzers. Mettler leads the market for weighing instrumentation and controls more than 50% of the market for lab balances. The business is geographically diversified, with the Americas accounting for about 37% of sales, Europe about 27%, China about 16% and the rest of the world about 20%.
96GF Score
Get the complete analysis for FRA:MTO
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:MTO has been successfully added to your 
